An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron - Nature.com

An inhibitor of the SARS-CoV-2 main protease (Mpro), Y180, showed therapeutic efficacy against wild-type SARS-CoV-2 and its variants including Omicron after oral administration and improved survival in a humanized mouse model.

Cell lines Huh7 (Cell Bank, Chinese Academy of Sciences, Shanghai, SCSP-526), BEAS-2B (Cell Bank, Chinese Academy of Sciences, Shanghai, GNHu27), A549 (ATCC, CRM-CCL-185), HUVEC (CCTCC, Wuhan, GDC06… [+20001 chars]

full article...